BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.
To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.
To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.
Reprints
Medicare officials say the federal health insurance program should restrict its coverage of the controversial new Alzheimer’s drug Aduhelm to patients who are participating in approved clinical trials, a move that would limit the number of patients who could use the expensive drug, the New York Times reports. In a preliminary decision released Jan. 11, the Centers for Medicare and Medicaid Services said it had concluded there remain significant doubts about whether the potential benefits of Aduhelm for patients outweigh the safety risks.
1. Hackers leak stolen data from Change Healthcare on dark web
2. UnitedHealth estimates $1.6 billion loss from Change cyberattack
3. UnitedHealth reports significant data breach; personal health info compromised
4. Ex-NBA player Will Bynum sentenced in insurance fraud scandal
5. Illinois House passes governor’s 'Healthcare Protection Act’
6. Analyst says Cigna, Humana share prices could put merger back on the table